Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716180 | 0.87 | PLK1 (0.51) | CYP3A4ALDH1A1SMN1; SMN2ACHEPOLB | |
| SCHEMBL12781853 | 0.87 | CYP3A4 (0.54) | CYP3A4ALDH1A1SMN1; SMN2ACHEPOLB | |
| SCHEMBL6968876 | 0.82 | CYP3A4 (0.47) | CYP3A4ALDH1A1SMN1; SMN2ACHEPOLB | |
| SCHEMBL3670353 | 0.82 | ALDH1A1 (0.47) | CYP3A4ALDH1A1SMN1; SMN2ACHEPOLB | |
| SCHEMBL6582676 | 0.81 | CYP3A4 (0.46) | CYP3A4ALDH1A1SMN1; SMN2ACHEPOLB | |
| SCHEMBL31405856 | 0.81 | CYP3A4 (0.46) | CYP3A4ALDH1A1SMN1; SMN2ACHEPOLB | |
| SCHEMBL31405855 | 0.80 | ALDH1A1 (0.48) | CYP3A4ALDH1A1SMN1; SMN2ACHEPOLB | |
| SCHEMBL10607668 | 0.78 | CYP3A4 (0.46) | CYP3A4ALDH1A1SMN1; SMN2ACHEPOLB | |
| SCHEMBL6583176 | 0.77 | CYP3A4 (0.45) | CYP3A4ALDH1A1SMN1; SMN2ACHEPOLB | |
| SCHEMBL31480904 | 0.77 | MEN1 (0.34) | CYP3A4ALDH1A1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373257-B9 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1373257-B9 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1373257-B1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1373257-B1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2007-11-28 | — | — | EP | disclosed |
| US-6949544-B2 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030087922-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087922-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | CDK2, LCK, CDK5 | CYP3A4 3526/4885ALDH1A1 4705/4885SMN1; SMN2 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.